<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121029</url>
  </required_header>
  <id_info>
    <org_study_id>EN10-011</org_study_id>
    <nct_id>NCT01121029</nct_id>
  </id_info>
  <brief_title>Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus</brief_title>
  <official_title>Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dra. Olga Graciela Cantu Rodriguez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if autologous nonmyeloablative hematopoietic stem
      cell transplantation is able to induce prolonged and significant increases of C-peptide
      levels associated with absence of or reduction of daily insulin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with type 1 DM depend on exogenous insulin administration for survival and for
      control of long-term complications. The best-established treatment is tight control of blood
      glucose achieved by frequent daily injections or continuous subcutaneous infusion of insulin,
      ie, intensive insulin therapy. Although insulin therapy has developed enormously, even the
      most modern technologies do not allow the maintenance of normoglycemia.

      Since the establishment of the autoimmune etiology of type 1 DM in the late 1970s, many
      clinical trials analyzing the effects of different types of immune interventions demonstrated
      that beta-cell preservation is an achievable target in different degrees.

      Controlled trials and further biological studies are necessary to confirm the role of this
      treatment in changing the natural history of type 1 DM.

      This is a prospective pilot study which will enroll patients with type 1 diabetes mellitus
      within the first months of diagnosis, with clinical and laboratory findings. The donor
      stimulation will be with cyclophosphamide, filgrastim, and mesna. The cells will be
      recollected from peripheral blood by apheresis and refrigerated. The patients will receive a
      nonmyeloablative conditioning regimen with cyclophosphamide and fludarabine, and after this,
      the cells will be injected intravenously. They will receive a standard regimen of
      post-transplant prophylaxis. The duration of use of this prophylactic drugs scheme depends on
      the patient's recovery time. The reinfusion of stem cells will be completed after the last
      dose of cyclophosphamide, through a peripheral vein.

      Lately, every three months, the C-Peptide levels, glucose and insulin serum levels will be
      measured.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-peptide levels before and after the hematopoietic stem cell transplantation</measure>
    <time_frame>Every 3 months for 1 year.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum levels of Hb A1C before and after the hematopoietic stem cell transplantation</measure>
    <time_frame>Every month for 1 year.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Hematopoietic stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous hematopoietic stem cell transplantation</intervention_name>
    <description>Patients will receive a stimulation with filgrastim 10mcg/Kg per day during 4 days and cyclophosphamide 1.5g/m2 per day during 2 days and mesna 300mg/m2 i.v. in 4 hours for prophylaxis (uroprotection). Lately, the stem cells will be recollected by apheresis. After that, the patients will receive a conditioning regimen with cyclophosphamide 500mg/m2 per day during 4 days and fludarabine 30mg/m2 per day during 4 days. After the last dose of cyclophosphamide, the autologous hematopoietic stem cell transplantation will be done on day 0, by peripheral vein. Then, a standard regimen of prophylaxis with oral ciprofloxacin 500mg every 12 hours, acyclovir 400mg every 8 hours, fluconazole 100mg per day and omeprazole 20mg per day for the recovery time of each patient.</description>
    <arm_group_label>Hematopoietic stem cells</arm_group_label>
    <other_name>Stem cell therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly diagnosed in type 1 diabetes mellitus

        Exclusion Criteria:

          -  Patients with HIV

          -  Patients with Hepatitis

          -  Patients with hematologic disease

          -  Patients with hearth failure

          -  Renal, Hepatic or psychiatric disease

          -  Pregnant patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando J Lavalle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Dr. José Eleuterio González</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Gómez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Dr. José Eleuterio González</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olga G Cantú, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Dr. José Eleuterio González</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Dr. José Eleuterio González</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Couri CE, Voltarelli JC. Potential role of stem cell therapy in type 1 diabetes mellitus. Arq Bras Endocrinol Metabol. 2008 Mar;52(2):407-15. Review.</citation>
    <PMID>18438552</PMID>
  </reference>
  <reference>
    <citation>Couri CE, Foss MC, Voltarelli JC. Secondary prevention of type 1 diabetes mellitus: stopping immune destruction and promoting beta-cell regeneration. Braz J Med Biol Res. 2006 Oct;39(10):1271-80. Epub 2006 Aug 22. Review.</citation>
    <PMID>16941054</PMID>
  </reference>
  <reference>
    <citation>Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Simões BP, Foss MC, Squiers E, Burt RK. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007 Apr 11;297(14):1568-76.</citation>
    <PMID>17426276</PMID>
  </reference>
  <reference>
    <citation>Voltarelli JC, Couri CE. Stem cell transplantation for type 1 diabetes mellitus. Diabetol Metab Syndr. 2009 Sep 16;1(1):4. doi: 10.1186/1758-5996-1-4.</citation>
    <PMID>19825196</PMID>
  </reference>
  <reference>
    <citation>Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med. 1998 Apr 1;128(7):517-23.</citation>
    <PMID>9518395</PMID>
  </reference>
  <reference>
    <citation>Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, Madeira MI, Malmegrim KC, Foss-Freitas MC, Simões BP, Martinez EZ, Foss MC, Burt RK, Voltarelli JC. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009 Apr 15;301(15):1573-9. doi: 10.1001/jama.2009.470.</citation>
    <PMID>19366777</PMID>
  </reference>
  <results_reference>
    <citation>Otonkoski T, Gao R, Lundin K. Stem cells in the treatment of diabetes. Ann Med. 2005;37(7):513-20. Review.</citation>
    <PMID>16278164</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <last_update_submitted>December 6, 2012</last_update_submitted>
  <last_update_submitted_qc>December 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>Dra. Olga Graciela Cantu Rodriguez</investigator_full_name>
    <investigator_title>Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

